# Questions From the Trial Record > Growth Hormone Axis Peptide FAQ — Sermorelin, Tesamorelin, Ipamorelin — bigtimepeptides — Frequently asked questions about three Growth Hormone Axis research peptides — sermorelin, tesamorelin, and ipamorelin — answered from the peer-reviewed literature, with citations. **GROWTH HORMONE AXIS / FAQ** Direct, citation-anchored answers to the questions readers most often bring to these three GH-axis peptides. ## What is sermorelin? Sermorelin is a synthetic peptide — specifically, the amino-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the shortest piece of the full 44-amino-acid hormone that still fully activates the GHRH receptor. It's administered as sermorelin acetate. It was previously FDA-approved under the brand name Geref for pediatric growth hormone deficiency, withdrawn from the market in 2008 for commercial reasons, and is available today mainly through compounding pharmacies [1]. ## What does sermorelin do to the body? Sermorelin binds the GHRH receptor on pituitary somatotroph cells, stimulating the pituitary to synthesize and release the body's own growth hormone in its normal pulsing pattern. The resulting GH drives IGF-1 production and is linked in community reports to sleep changes, body-composition shifts, and recovery effects — though those community reports are anecdotal, not clinical findings [1]. ## Does sermorelin work? For its historical approved use — pediatric growth hormone deficiency — yes: a multicenter trial found once-daily sermorelin accelerated linear growth, lifting first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without driving IGF-1 to excessive levels [5]. For newer, off-label wellness and anti-aging uses in adults, the evidence is thinner; an Annals of Internal Medicine editorial concluded that using growth hormone secretagogues for anti-aging purposes is 'not yet ready for prime time' [3]. ## How long does it take for sermorelin to work? There's no controlled human timeline published specifically for sermorelin's onset in adult wellness use. Community reports consistently describe sermorelin as a 'slow burn' — the first month often feels like nothing is happening, with sleep and energy changes typically not clearly noticeable until the second or third month of consistent nightly use. Those reports are anecdotal, not clinical evidence, and aren't a guarantee of any particular timeline or outcome. ## What is tesamorelin? Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), chemically stabilized with a trans-3-hexenoic acid group at the amino end to resist enzymatic breakdown. It's FDA-approved (2010) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy — the only active FDA approval among the three peptides tracked on this site [7]. ## What does tesamorelin do? Tesamorelin stimulates the pituitary to release the body's own growth hormone, which in turn drives the liver to produce IGF-1; together they promote fat breakdown with a documented preference for visceral fat — the fat around internal organs. In its approved population, a 2026 meta-analysis of five RCTs found it reduced visceral adipose tissue by a mean of 27.71 cm2 and increased lean body mass by 1.42 kg [6]. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotroph cells, activating the same signaling cascade the body's own GHRH uses, which stimulates pulsatile growth hormone release. Because it amplifies the body's natural GH rhythm rather than replacing GH directly, its metabolic profile in trials differs from recombinant growth hormone — notably, a study in healthy men found no significant change in fasting glucose or insulin sensitivity over two weeks of dosing [9]. ## Will tesamorelin help me lose belly fat? This site can't answer that for any individual — it isn't medical advice. What the trial record shows: in its approved population (HIV-associated lipodystrophy), tesamorelin has repeatedly reduced visceral adipose tissue in controlled trials — by 15.2% in the pivotal 26-week Phase 3 trial and by a pooled 27.71 cm2 across a 2026 meta-analysis of five RCTs [6][11]. That benefit is contingent on continued dosing: visceral fat reaccumulated within weeks once patients in the 52-week trial stopped the drug [10]. Effectiveness outside the studied HIV population is not established by large controlled trials. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a), triggering a pulse of growth hormone release through a mechanism distinct from the GHRH-receptor peptides sermorelin and tesamorelin. It has never been approved as a drug by any regulator and is sold as a research chemical. ## What does ipamorelin do for you? Mechanistically, it triggers a pulse of growth hormone release from the pituitary without meaningfully raising cortisol, ACTH, or prolactin — a selectivity that distinguishes it from older GH-releasing peptides [16]. Beyond that mechanism, controlled human evidence is thin: its one published Phase 2 trial, testing whether it would speed bowel-function recovery after surgery, missed its primary endpoint [15]. Community reports describe sleep and recovery effects, but those are anecdotal, not clinical findings. ## What is ipamorelin peptide? It's the same compound as 'ipamorelin' above — a five-amino-acid synthetic peptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from an earlier peptide (GHRP-1) by removing a central two-amino-acid segment. It's sometimes referenced by the code NNC 26-0161 in the pharmacology literature. ## What are the risks of ipamorelin? The literature flags several mechanistic and evidentiary cautions: GH-axis stimulation raises IGF-1, a mitogen, which is a theoretical (not established) cancer-related concern; ipamorelin has shown a direct, GH-independent insulin-releasing effect in laboratory pancreatic tissue, making its net effect on blood sugar in someone with existing insulin dysregulation hard to predict; and a chronic 28-day dosing study of a related — not identical — ghrelin-receptor agonist found dose-dependent heart-muscle toxicity in rats, a class-level signal with no equivalent long-duration study of ipamorelin itself [14]. More broadly, the entire confirmed human ipamorelin safety dataset comes from one short perioperative trial and one small acute-dosing study — there's no long-term human safety data, and research-grade material's purity is unverified [15][16]. --- bigtimepeptides is an independent research digest on the growth-hormone axis — not a pharmacy, not a clinic, and not a source for any of the compounds it writes about.